文献速递甲状腺疾病

甲状腺癌中的FGFR改变:一类具有重要治疗意义的新型原发驱动因素以及可能介导甲状腺恶性肿瘤耐药性的继发性分子事件

FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy.
PubMed 文献 · Thyroid · 2024-08-07

该多中心回顾性观察研究分析了5030例测序的甲状腺恶性肿瘤,检出17例存在FGFR家族基因改变,其中11例为原发驱动(9例基因融合、2例FGFR1扩增),6例为继发性改变。研究首次描述了以FGFR原发驱动改变分组的甲状腺癌集合,并指出识别FGFR改变对患者具有重要治疗意义,因目前文献中认识不足且存在潜在新型治疗选择。

要点

  • 5030例甲状腺恶性肿瘤中检出17例FGFR改变,11例为原发驱动、6例为继发性改变。
  • 11例FGFR驱动肿瘤中9例为基因融合(FGFR2:VCL 4例、TG::FGFR1 3例等),2例为FGFR1扩增。
  • 6例继发性改变包括FGFR2 p.W290C、p.Y375C、p.N549K及FGFR1 p.N546K,部分为亚克隆变异等位基因频率。

核心结论

  • 本研究首次描述了按FGFR原发驱动改变分组的甲状腺癌集合,以及一组具有继发性改变、可能促进肿瘤进展或靶向治疗耐药的甲状腺肿瘤。
  • 鉴于存在靶向致癌性FGFR的小分子抑制剂,作者强调识别FGFR改变对患者具有重要治疗意义,因目前文献中认识不足且存在潜在新型治疗选择。

研究设计与样本

  • 多中心回顾性观察研究,查询各中心积累的甲状腺癌分子数据,纳入FGFR基因家族致病性改变的甲状腺癌。
  • 共回顾5030例测序的甲状腺恶性肿瘤,检出17例FGFR改变肿瘤,其中11例FGFR为原发分子驱动、6例FGFR为继发性致病改变,部分病例有可用临床随访数据。

主要发现

  • 11例FGFR驱动癌中,9例为基因融合:FGFR2:VCL(4例)、TG::FGFR1(3例)、FGFR2::CIT、FGFR2::SHTN1;其余2例由FGFR1扩增驱动。
  • 6例存在甲状腺肿瘤经典驱动(5例)或未检出明确原发驱动(1例)的肿瘤中,测序检出继发性FGFR2 p.W290C、p.Y375C、p.N549K及FGFR1 p.N546K,位于相应酪氨酸激酶结构域,部分为亚克隆变异等位基因频率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Diagnostic classification of thyroid malignancy is primarily accomplished through examination of histomorphological features and may be substantiated and clarified by molecular data. Individual molecular drivers show relatively robust and specific associations with histological subtypes of thyroid malignancy, including BRAF sequence variants and kinase gene fusions in papillary thyroid carcinoma, predominantly RAS variants in follicular-patterned neoplasia, and additional "late" mutations affecting TERT promoter, TP53, and the PI3K/AKT/PTEN pathway in high-grade malignancies. Given the oncogenic role of FGFR, particularly FGFR1-3, the goal of this study was to explore the role of FGFR in thyroid carcinoma biology. Methods: We completed a multicenter retrospective observational study for thyroid carcinomas with pathogenic alterations in the FGFR gene family. We performed this study by querying the molecular data accumulated for thyroid carcinomas from each center. Results: Overall, 5030 sequenced thyroid malignancies were reviewed, yielding 17 tumors with FGFR alterations, including 11 where FGFR was the primary molecular driver and 6 where FGFR was a secondary pathogenic alteration, with a subset for which there was available clinical follow-up data. Of the 11 carcinomas with an FGFR driver, 9 were gene fusions involving FGFR2:VCL (4 tumors), TG::FGFR1 (3 tumors), FGFR2::CIT, and FGFR2::SHTN1, and the remaining 2 were driven by FGFR1 amplification. In the 6 tumors where a canonical driver of thyroid neoplasia was present (5 cases) or no clear primary driver was detected (1 case), sequencing detected secondary FGFR2 p.W290C, p.Y375C, and p.N549K, as well as FGFR1 p.N546K in the respective tyrosine kinase domains, some at subclonal variant allele frequencies. Conclusions: This study presents the first description of a collection of thyroid carcinomas grouped by primary driver alterations in FGFR, as well as a cohort of thyroid tumors with secondary alterations that potentially lead to tumor progression or resistance to targeted therapy. Given the availability of small molecular inhibitors targeting oncogenic FGFR, this study emphasizes the significant implications for patients from identification of FGFR alterations as they are currently under-recognized in the literature and, most importantly, have potential novel treatment options.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Sabbagh MF, Janovitz T, Dias-Santagata D, et al. FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy. Thyroid. 2024. PMID: 39003525. doi:10.1089/thy.2024.0216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。